Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AD-231 vs Coadministration of AD-231A, AD-231D and AD-231C
NCT07590167Phase 1Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AD-231A in dyslipidemia and hypertension (HTN) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Maximum concentration of drug in plasma at 72 hours and Area under the plasma concentration-time curve during dosing interval at 72 hours. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
AD-231A
03
Conditions
dyslipidemiahypertension (HTN)
Beyond the preview
Go deeper on NCT07590167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07590167.